News|Articles|November 18, 2026

ASRA Case Highlights When to Reassess Cannabis Use for Chronic Pain

Listen
0:00 / 0:00

Key Takeaways

  • Reframing assessment around functional change—especially nocturnal awakenings and repositioning frequency—can quantify loss of benefit and guide follow-up beyond static pain scores.
  • Treatment selection reflected pulmonary risk, avoiding opioids and pivoting toward low-dose naltrexone and trigger point injections when myofascial pain became refractory.
SHOW MORE

Cannabinoids pain management may need a pharmacist’s reassessment, as an ASRA Pain Medicine case report shows.

A 20-year-old man with spinal muscular atrophy type 2 reported that cannabis initially eased his chronic myofascial pain. Over time, his pain worsened despite continued twice-daily use.

The case, presented at ASRA Pain Medicine’s 25th Annual Pain Medicine Meeting in Tampa, Florida, highlights a question pharmacists can ask when a patient reports that cannabis used to help: What has changed in their daily life since they started using it?¹

How the Care Team Responded to Worsening Pain

The patient reported pain in his lower back and around his ribs and shoulder blade. He rated it 8 out of 10 and needed to reposition about every 45 minutes at night, disrupting his sleep. Acetaminophen, topical lidocaine, and several oral muscle relaxants had provided minimal relief. His care team deferred opioid therapy because of restrictive lung disease and the risk of hypoventilation. The team started low-dose naltrexone and planned trigger point injections.¹

The authors described counseling that addressed the patient’s diminished pain relief and persistent low mood. The abstract leaves the cause of his worsening pain uncertain and provides no follow-up outcomes after the treatment changes.¹ The nighttime repositioning is especially relevant to a pharmacist’s assessment. Asking how often pain interrupts sleep gives the patient a concrete way to describe whether relief has lasted and how much the symptoms are affecting daily life.

Match the Evidence to the Product and Pain Condition

The evidence for sustained benefit is limited. An updated systematic review in Annals of Internal Medicine included 25 randomized trials with 2303 participants. Most participants had neuropathic pain, and the trials lasted 1 to 6 months. Compared with placebo, oral synthetic or purified tetrahydrocannabinol (THC) products were associated with a pooled reduction of 0.78 points on a 0-to-10 pain scale.

Extracted oral sprays with comparable amounts of THC and cannabidiol (CBD) were associated with a 0.54-point reduction. Both product categories carried higher risks of dizziness, sedation, and nausea.² These results leave substantial uncertainty about longer-term use for myofascial pain.

A broader Agency for Healthcare Research and Quality review found that oral CBD alone showed no clear improvement in pain or function compared with placebo. The review also found insufficient evidence to determine the effect of cannabinoids on opioid use.³ When a patient asks whether a CBD product is likely to restore pain relief or allow them to use less of a prescribed analgesic, the pharmacist can explain those limits and bring the prescriber into the discussion before the patient changes their regimen.

Ask What the Patient Takes and What Has Changed

The case abstract describes twice-daily use. It leaves the formulation and THC or CBD content unspecified.¹ In practice, a photo of the label can help identify the route, the labeled amount per serving, and the amount the patient actually takes. Ask whether they switched products or began using them more often after the benefit faded. Formulations sold in dispensaries may contain substantially more THC than the products studied in trials, according to the American College of Physicians (ACP).⁴

Medication reconciliation can also explain why a patient feels less able to function even when their pain score has barely changed. The FDA warns that CBD can interact with other medications and that combining it with alcohol or drugs that slow central nervous system activity can increase drowsiness.⁵ Asking about sleep aids, alcohol, and daytime alertness can surface problems the patient may have attributed to poor sleep. The ACP also advises clinicians to counsel young adults that the harms of cannabis or cannabinoid use for chronic noncancer pain are likely to outweigh the benefits.⁴

A pharmacist can send the prescriber a concise account of the product, how the patient’s use has changed, and the symptom that is hardest to manage. For someone whose pain regularly wakes them, tracking nighttime awakenings gives the patient and care team a practical measure to revisit at follow-up.

REFERENCES
  1. ASRA Pain Medicine. Chronic cannabis use and refractory myofascial pain in adult spinal muscular atrophy type 2. Case abstract presented at: 25th Annual Pain Medicine Meeting; November 7, 2026; Tampa, FL. Session EXP-07-S3. Accessed November 18, 2026. https://epostersonline.com/asrafall2026/node/472
  2. Chou R, Fu R, Ahmed AY, Morasco BJ. Cannabis-Based Products for Chronic Pain : An Updated Systematic Review. Ann Intern Med. 2026;179(2):230-241. doi:10.7326/ANNALS-25-03152
  3. Chou R, Ahmed AY, Dana T, et al. Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain: 2025 Update [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2025 Jul. (Comparative Effectiveness Review, No. 250.)Available from: https://www.ncbi.nlm.nih.gov/books/NBK618045/doi: 10.23970/AHRQEPCCER250UPDATE2025
  4. Kansagara D, Hill KP, Yost J, et al. Cannabis or Cannabinoids for the Management of Chronic Noncancer Pain: Best Practice Advice From the American College of Physicians. Ann Intern Med. 2025;178(5):714-724. doi:10.7326/ANNALS-24-03319
  5. US Food and Drug Administration. What you need to know (and what we’re working to find out) about products containing cannabis or cannabis-derived compounds, including CBD. Accessed November 18, 2026.https://www.fda.gov/consumers/consumer-updates/what-you-need-know-and-what-were-working-find-out-about-products-containing-cannabis-or-cannabis

Related to this article

Two pharmacists in a pharmacy -- Image credit: Krakenimages.com | stock.adobe.com
Balanced exposure to clinical and nonclinical careers, timed to each pathway's application calendar and built into each curriculum's structure, can help pharmacy students choose their next step deliberately.